© 2004 by Oxford University Press
© 2004 Oxford University Press
CORRESPONDENCE |
Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)
Affiliations of authors: Medical Research Council Clinical Trials Unit, London, U.K. (GR); The Australian and New Zealand Gynaecological Oncology Group, Victoria, Australia (MQ); The Gynecologic Oncology Group, Philadelphia, PA (TT); Arbeitsgemeinschaft Gynaekologische Onkologie (ADB); Group d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens, Paris, France (EPL); The Nordic Society of Gynecological Oncology, Linkóping, Sweden (AJ); National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada (EE); Japanese Gynecologic Oncology Group, Tokyo, Japan (SS); Radiation Therapy Oncology Group, Philadelphia (KG); The European Organisation for Research and Treatment of Cancer, Brussels, Belgium (IV); Spanish Group for Research on Ovarian Cancer, Barcelona, Spain (AC); Gynaecologic Cancer Intergroup, Bethesda, MD (JV)
Correspondence to: Gordon J. S. Rustin, MD, FRCP, Mount Vernon Hospital, Department of Medical Oncology, The Clock Tower, Northwood, Middlesex, HA6 2RN, U.K. (e-mail: gordon.rustin@whht.nhs.uk)
| The first 10% of the full text of this article appears below. |
The Gynaecologic Cancer Intergroup (GCIG) believes that definitions for response and progression of ovarian cancer according to serum CA 125 levels should be incorporated into ovarian cancer clinical trial protocols for relapse therapy. Although the GCIG is convinced of the value of the definition of progression that incorporates both Response Evaluation Criteria in Solid Tumors (RECIST) and CA 125
Correspondence about this Article
CiteULike 
Connotea 
Del.icio.us What's this?
J Natl Cancer Inst 2005 97: 151.
J Natl Cancer Inst 2005 97: 152.
This article has been cited by other articles:
|
|
 |
|
  J. L. Gulley, P. M. Arlen, K.-Y. Tsang, J. Yokokawa, C. Palena, D. J. Poole, C. Remondo, V. Cereda, J. L. Jones, M. P. Pazdur, et al. Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma Clin. Cancer Res., May 15, 2008; 14(10): 3060 - 3069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Rader, C. F. Aylsworth, D. A. Juckett, D. G. Mutch, M. A. Powell, L. Lippmann, and N. V. Dimitrov Phase I Study and Preliminary Pharmacology of the Novel Innate Immune Modulator rBBX-01 in Gynecologic Cancers Clin. Cancer Res., May 15, 2008; 14(10): 3089 - 3097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P.B. O'Connor, G. C. Jayson, A. Jackson, D. Ghiorghiu, B. M. Carrington, C. J. Rose, S. J. Mills, R. Swindell, C. Roberts, C. L. Mitchell, et al. Enhancing Fraction Predicts Clinical Outcome following First-Line Chemotherapy in Patients with Epithelial Ovarian Carcinoma Clin. Cancer Res., October 15, 2007; 13(20): 6130 - 6135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Marsh, J. Paul, C. R. King, G. Gifford, H. L. McLeod, and R. Brown Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer J. Clin. Oncol., October 10, 2007; 25(29): 4528 - 4535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Tummala and W. P. McGuire Ovarian Cancer, CA-125 Addiction, and Informed Confusion: Much Ado About Less J. Clin. Oncol., August 20, 2007; 25(24): 3570 - 3571. [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Coleman, A. Gordon, J. Barter, S. Sun, W. Rackoff, and T. J. Herzog Early Changes in CA125 After Treatment with Pegylated Liposomal Doxorubicin or Topotecan Do Not Always Reflect Best Response in Recurrent Ovarian Cancer Patients Oncologist, January 1, 2007; 12(1): 72 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J.S. Rustin, P. Timmers, A. Nelstrop, G. Shreeves, S. M. Bentzen, B. Baron, M. J. Piccart, K. Bertelsen, G. Stuart, J. Cassidy, et al. Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide J. Clin. Oncol., January 1, 2006; 24(1): 45 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T. Taylor and D. Haverstick Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer) J Natl Cancer Inst, January 19, 2005; 97(2): 151 - 151. [Full Text] [PDF]
|
|
|
|
|
|
G. J.S. Rustin Can We Now Agree to Use the Same Definition to Measure Response According to CA-125? J. Clin. Oncol., October 15, 2004; 22(20): 4035 - 4036. [Full Text] [PDF]
|
|